A randomized, open-label, three-group trial evaluated the effectiveness of hydroxychloroquine alone or with azithromycin in patients with mild-to-moderate Covid-19. The study included 667 patients hospitalized with suspected or confirmed Covid-19, randomly assigned to receive standard care, hydroxychloroquine alone, or hydroxychloroquine plus azithromycin. The primary outcome was clinical status at 15 days, assessed using a seven-level ordinal scale. Results showed no significant difference in clinical outcomes between the groups. Hydroxychloroquine alone or in combination with azithromycin did not improve clinical status compared to standard care. Adverse events, including QT interval prolongation and elevated liver enzymes, were more common in patients receiving hydroxychloroquine. The study concluded that hydroxychloroquine, alone or with azithromycin, did not improve clinical outcomes in patients with mild-to-moderate Covid-19. The trial was funded by the Coalition Covid-19 Brazil and EMS Pharma.A randomized, open-label, three-group trial evaluated the effectiveness of hydroxychloroquine alone or with azithromycin in patients with mild-to-moderate Covid-19. The study included 667 patients hospitalized with suspected or confirmed Covid-19, randomly assigned to receive standard care, hydroxychloroquine alone, or hydroxychloroquine plus azithromycin. The primary outcome was clinical status at 15 days, assessed using a seven-level ordinal scale. Results showed no significant difference in clinical outcomes between the groups. Hydroxychloroquine alone or in combination with azithromycin did not improve clinical status compared to standard care. Adverse events, including QT interval prolongation and elevated liver enzymes, were more common in patients receiving hydroxychloroquine. The study concluded that hydroxychloroquine, alone or with azithromycin, did not improve clinical outcomes in patients with mild-to-moderate Covid-19. The trial was funded by the Coalition Covid-19 Brazil and EMS Pharma.